US2021346511A1PendingUtilityA1

Immunoconjugates with an intracellularly-cleavable linkage

81
Assignee: IMMUNOMEDICS INCPriority: Dec 13, 2002Filed: Apr 21, 2021Published: Nov 11, 2021
Est. expiryDec 13, 2022(expired)· nominal 20-yr term from priority
Inventors:David M. GoldenbergSerengulam V. GovindanSung-Ju Moon
C07K 16/1145A61K 47/68037A61K 47/6853Y02A50/30A61K 2039/505A61K 47/6859A61P 35/00A61K 47/6889A61K 31/4745A61K 47/6841C07K 16/3046A61K 45/06A61P 31/00A61P 31/18A61P 29/00A61K 47/6851A61K 47/6861A61K 47/6855C07D 491/22C07K 16/2863C07K 2317/31A61K 47/6849C07K 2317/40C07K 2317/52C07K 2317/21C07K 16/2833A61P 17/00A61P 35/04A61N 5/10C07K 16/303C07K 2317/53C07K 2317/24C07K 16/18A61P 31/04C07K 16/2803A61P 37/06C07K 16/30A61P 37/02C07K 2317/94A61K 47/6857C07K 16/3092C07K 16/3076A61P 31/12C07K 16/2887C07K 16/1063A61K 47/6803
81
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

Claims

exact text as granted — not AI-modified
1 . An antibody-drug conjugate (ADC) having a structural formula MAb-CL2A-SN-38, with a structure represented by: 
       
         
           
           
               
               
           
         
       
       wherein the MAb is hMN-14. 
     
     
         2 . The antibody-drug conjugate of  claim 1 , wherein the MAb is a monoclonal antibody or an antigen binding antibody fragment. 
     
     
         3 . The antibody-drug conjugate of  claim 2 , wherein said fragment is selected from the group consisting of Fab, Fab′, F(ab) 2 , F(ab′) 2 , and scFv. 
     
     
         4 . The antibody-drug conjugate of  claim 2 , wherein the MAb has constant domains and a hinge domain of a human IgG1 antibody. 
     
     
         5 . The antibody-drug conjugate of  claim 1 , wherein said MAb is attached to between 1 and 12 copies of CL2A-SN38. 
     
     
         6 . The antibody-drug conjugate of  claim 1 , wherein said MAb is attached to between 6 and 8 copies of CL2A-SN38. 
     
     
         7 . The antibody-drug conjugate of  claim 1 , wherein said MAb is attached to between 1 and 5 copies of CL2A-SN38.

Join the waitlist — get patent alerts

Track US2021346511A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.